Related Experiment Videos
Local cutaneous allergy to monocomponent insulin.
Postgraduate Medical Journal
|March 1, 1979
Summary
Local skin reactions, a type of hypersensitivity, were observed in a patient shortly after starting treatment with monocomponent insulins (MCI). This case report details the first known instance of this specific adverse reaction to MCI therapy.
Area of Science:
- Endocrinology
- Dermatology
- Immunology
Background:
- Diabetes mellitus management often involves insulin therapy.
- Monocomponent insulins (MCI) are purified insulin preparations designed to minimize allergic reactions.
- Hypersensitivity reactions to insulin, though rare with modern formulations, can occur.
Observation:
- A patient receiving treatment with monocomponent insulins (MCI) developed localized skin hypersensitivity.
- The hypersensitivity manifested as a local cutaneous reaction shortly after initiating MCI treatment.
- This reaction was observed in the context of standard diabetes care.
Findings:
- The case presents the first documented instance of local cutaneous hypersensitivity specifically linked to monocomponent insulins (MCI).
- The findings suggest that even highly purified insulins can potentially elicit hypersensitivity responses in susceptible individuals.
- The temporal association indicates MCI as the likely causative agent for the observed skin reaction.
Implications:
- Clinicians should be aware of the potential for cutaneous hypersensitivity reactions to MCI, even if rare.
- This case highlights the importance of considering all insulin types, including MCI, in the differential diagnosis of skin reactions in diabetic patients.
- Further investigation may be warranted to understand the mechanisms underlying MCI-induced hypersensitivity and identify risk factors.